Stock Events

Stock Events

Savara 

$5.64
53
+$0+0% Wednesday 02:45

Statistics

Day High
5.64
Day Low
5.63
52W High
-
52W Low
-
Volume
42
Avg. Volume
-
Mkt Cap
1.15B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.14
-0.13
-0.13
-0.12
Expected EPS
-0.135
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-191.76MNet Income

Analyst Ratings

$9.80Average Price Target
The highest estimate is 11.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SVRA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a key area of focus for Savara.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, focusing on serious respiratory conditions, among other areas, which overlaps with Savara's interests.
Insmed
INSM
Mkt Cap40.44B
Insmed Incorporated specializes in rare lung diseases, directly competing with Savara's development of treatments for similar conditions.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals is involved in developing therapies for lung-related diseases, making it a direct competitor to Savara.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV focuses on developing drugs for inflammatory diseases, including those affecting the lungs, positioning it as a competitor.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, while primarily focused on genetic medicine for rare diseases, represents broader competition in the biotech sector for companies like Savara.
Protagonist Therapeutics
PTGX
Mkt Cap4.89B
Protagonist Therapeutics is engaged in developing peptide-based drugs, a method that could be applied to conditions similar to those Savara targets, making them competitors.

About

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Show more...
CEO
ISIN
US8051111016

Listings

XNAS
US
SVRA
F
DE
YB4P.F
BOATS
BOATS
SVRA.BOATS

0 Comments

Share your thoughts

FAQ

What is Savara stock price today?▼
The current price of SVRA.BOATS is $5.64 USD — it has increased by +0% in the past 24 hours. Watch Savara stock price performance more closely on the chart.
What is Savara stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Savara stocks are traded under the ticker SVRA.BOATS.
What is Savara market cap?▼
Today Savara has the market capitalization of 1.15B
When is the next Savara earnings date?▼
Savara is going to release the next earnings report on May 07, 2026.
What were Savara earnings last quarter?▼
SVRA.BOATS earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.12 USD resulting in a -9.47% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Savara revenue for the last year?▼
Savara revenue for the last year amounts to 0 USD.
What is Savara net income for the last year?▼
SVRA.BOATS net income for the last year is -191.76M USD.
When did Savara complete a stock split?▼
Savara has not had any recent stock splits.